Curriculum Vitae

Name: Matthew Kay

Address/Info: 1404 Moffet Road

Silver Spring, MD 20903

E-mail address: ac54o9@r.postjobfree.com

Contact Telephone: 512-***-**** (cell)

https://www.linkedin.com/in/dr-matt-kay-a8116297/

Citizenship: United States

Education: Ph.D. in Biomedical Sciences, Immunology and Infectious Diseases (2010 - 2015)

Texas Tech University Health Sciences Center, Lubbock, TX Master of Science, Biology (2007 - 2010)

Texas State University, San Marcos, TX

Bachelor of Science, Microbiology (1998 - 2003)

University of Texas at Austin, Austin, TX

Experience: Director of Microbiology (2017 - 2018) Adaptive Phage Therapeutics, Gaithersburg, MD

Postdoctoral Research Fellow (2015 - 2017)

NAMRU-SA JBSA Fort Sam Houston, San Antonio, TX

Research Assistant (2010 - 2015)

Texas Tech University Health Sciences Center, Lubbock, TX Instructional Assistant (2008 - 2010)

Texas State University, San Marcos, TX

Testing Technologist I (2005 - 2007)

BIOMAT USA, Austin, TX

Qualifications Summary:

Director of Microbiology with Adaptive Phage Therapeutics in (1) Customized phage preparations for critically-ill eIND cases with multi-drug resistant bacterial infections and (2) State-of-the-art laboratory facilities for clinical phage production to meet FDA- and GMP -level requirements.

o Worked in conjunction with Navy's Biological Defense Research Directorate in Fort Detrick, MD to screen libraries for phage effective against patient strains. Moved these screening processes successfully into new lab at APT. o Answered CMC production questions in Pre-IND Meeting with the FDA. Wrote many versions of SOPs for phage production, batch records, and other GMP-related documents.

o Researched optimal methods of amplifying phage for human use, including tangential flow filtration and CsCl equilibrium gradients, with a focus on post- processing endotoxin removal from final lysates.

Postdoctoral Research Fellow with ORISE at NAMRU-SA in (1) Genetically recombineered E. coli phage displaying antimicrobial peptides (AMPs) against biofilms and (2) Display phage screening anti-snake venom antigens to specifically deliver M13 phage to inhibit venom phospholipase and other component activities. o Designed plasmid vectors carrying AMP cassettes to insert into phage genomes. Tested AMPs and phage on P. aeruginosa in multiple environments. o Set up apparatus that recirculated phage display libraries to bind specific snake venom antigens and inhibit target toxin active sites. o Performed grant writing, three preproposals accepted and 2 full proposals reviewed. Global Health Engagement grant accepted.

Research Assistant at TTUHSC in (1) Probiotic Biotherapeutic for Countermeasures against Cholera Toxin Project and (2) Broad Host Range Yersinia Phage Cocktail Project which were funded by the Army. Initiated and designed the research protocols, supervised data collection, analysis and presentation/publication. o Infected E. coli normal flora of mice with display phage expressing peptide that neutralized cholera toxin as a probiotic for cholera prophylaxis. Developed genetically engineered E. coli that could transfer the cholera neutralizing phage to the normal flora E. coli.

o Performed genetic manipulation of phage and phage cocktail to target both planktonic and biofilm bacteria and to expand the host-range of a Yersinia pestis phage cocktail.

o Used a non-functional TolC efflux construct, TolC-Tev379, to isolate and characterize mutant TolC-specific assembly and chaperone genes. Funded Projects:

1. Title: “Development of a Genetically Engineered Bacteriophage Cocktail with Enhanced Biofilm-Degrading Capability for the Treatment of Periodontal Pathogens” Funding Agency: NMRC’s Advanced Medical Development Program (G1313) Role: Technical Specialist – experimental design, technical applications, data analysis and manuscript submission

Funding Award: $1,283,085

Start/End: FY14-FY17

2. Title: “M13 Display Phages as Universal Antivenom” Funding Agency: Navy In-House Laboratory Independent Research Program (ILIR- 5160)

Role: Technical Specialist – experimental design, technical applications, data analysis and manuscript submission

Funding Award: $51,063

Start/End: FY16

Projects Invited for a Full Proposal:

1. Title: “Innovative Treatment Approaches using New Phage-Based Antimicrobials for the Treatment of Emerging Multi-drug Resistant Organisms” Funding Agency: Defense Medical Research and Development Program 2017

(DM170275P1)

Role: Designed, developed, prepared and submitted the proposal; arranged collaboration with the Biological Defense Research Directorate/Infectious Disease Directorate of NMRC

Requested Budget: $1.6M

Start/End: FY17-FY19

Progress: Invitation to submit an application on 3/2016; full application submission on 5/2016

2. Title: “Development of Universal Snakebite Antivenom using Display Phage” Funding Agency: Department of Defencse Global Health Engagement Research Program

Role: Designed, developed, prepared and submitted the proposal; arranged collaboration with the National Natural Toxins Research Center/Texas A&M University-Kingsville, TX

Requested Budget: $900,000

Start/End: FY17-FY18

Progress: Invitation to submit an application on 3/2016; full application submission on 6/2016

Professional Membership:

Full member of American Society for Microbiology

Full member of International Society for Viruses of Microorganisms Honors and Awards:

1. 3rd place award poster presentation: "Active Phage Infections on Clinically- Relevant Mature E. coli Biofilms using a lux Chemiluminescent Marker." ASM Conference Fall 2012 at Baylor University

2. Fall 2012 Texas ASM Branch Meeting Award

3. George H. Meyer Award in Microbiology at Texas State University, 2010 4. Presented thesis research at Texas State Biology Colloquium 2010, Texas ASM Branch Fall and Spring Meetings 2009-2010

Publications and Presentations:

Aslam S, Yung G, Dan J, Reed S, LeFebvre M, Logan C, Taplitz R, Law N, Golts E, Afshar K, Strathdee S, Lehman S, Morales S, Furr C, Rosas F, Gaidamaka A, Bilinsky I, Grint P, Biswas B, Duplessis C, Hamilton T, Merril G, Kay M, Trigg M, Sisson B, Henry M, Quinones J, Schooley RT. "Bacteriophage Therapy as an Adjunct to Systemic Antibiotics for Treatment of Multi-drug Resistant Pseudomonas aeruginosa Pneumonia in a Lung Transplant Recipient." To be published in 2018. Appl Environ Microbiol.

Titus J, Kay M, Glaser J, Hwang Y. "Application of phage display for the development of a novel inhibitor of PLA2 activity in Western cottonmouth venom." J Venom Res. 2017. 8: 19-24.

Horton TM, Kay M, Ertas A, Tate D. "A Hyperspectral Signature Method for Identifying E. coli: Impact on Public Health." Transdisciplinary Journal of Engineering

& Science. 2016. 7: 20-32.

Kay M, Erwin TC, McLean RJ, Aron GM. "Bacteriophage Ecology in Escherichia coli and Pseudomonas aeruginosa Mixed-Biofilm Communities." Appl Environ Microbiol. 2011 Feb. 77 (3): 821-829.

Watters C, Kay M, Rumbaugh S, Iqbal A, et al. Antibiofilm Agents: From Diagnosis to Treatment and Prevention. "Eradication of Wound Biofilms by Electrical Stimulation." 2014. 1st Ed. Pages 425-442.

Kay M, NAMRU-SA Public Affairs. 2016. NAMRU-San Antonio Presented at ASM Microbe Meeting to Help Fight Drug Resistant Pathogens. Naval Medical Research and Development News. Volume 8(7): 9-11.

Kay M, Titus J, Hwang Y. “Expression of Antimicrobial Peptides in Pseudomonas aeruginosa using Genetically Modified Phages for the Treatment of Periodontal Infections.” Poster presentation for MHSRS 2016. Gaylord Palms Resort and Convention Center, Kissimmee, FL.

Kay M, Fralick JA. Development of a Mixed Phage Cocktail against Environmental Isolates recovered from the Water System aboard the ISS. NASA project under NDA contract.

Kay M, Fralick JA. Development of a Broad Host Range Yersinia Phage Cocktail for Countermeasures. Presented in poster format at Baylor 2012 Texas Branch American Society for Microbiology Conference and won 3rd place, also presented at TTUHSC Student Research Week 2013. Due to Army sequestration, however, we declined to continue this project and did not pursue publication. Kay M, Fralick JA. The Effect of lpcA Mutation on TolC Drug-Efflux Activity. Presented in poster format at the 2013 Cell Membrane and Protein Research, 2013 Texas Branch ASM, and also at the 2014 TTUHSC Student Research Week conferences.

Kay M, Fralick JA. Use of a Tev27 Insertion in TolC to Locate Suppressor Mutations in TolC Assembly Proteins. Presented at the 2014 Cell Membrane Protein Research and Texas Branch ASM conferences.

References:

Joe A. Fralick, PhD

Professor, Dept of Immunology and Molecular Microbiology TTUHSC, Lubbock, TX

ac54o9@r.postjobfree.com

806-***-**** (lab)

806-***-**** (cell)

Nicholas J. Hamlin, PhD, DDS, MS

Lieutenant Commander, DC, USN

Head, Biomaterials & Environmental Surveillance Dept NAMRU-SA, San Antonio, TX

ac54o9@r.postjobfree.com

210-***-**** (lab)

619-***-**** (cell)

Biswajit Biswas, PhD

Senior Scientist, Phage Division Chief

Naval Medical Research Center, Fort Detrick, MD

ac54o9@r.postjobfree.com

301-***-**** (cell)

Contact this candidate